vs
PUMA BIOTECHNOLOGY, INC.（PBYI）とVIEMED HEALTHCARE, INC.（VMD）の財務データ比較。上の社名をクリックして会社を切り替えられます
VIEMED HEALTHCARE, INC.の直近四半期売上が大きい（$76.2M vs $75.5M、PUMA BIOTECHNOLOGY, INC.の約1.0倍）。PUMA BIOTECHNOLOGY, INC.の前年同期比売上増加率が高い（27.7% vs 25.5%）。PUMA BIOTECHNOLOGY, INC.の直近四半期フリーキャッシュフローが多い（$14.4M vs $9.7M）。過去8四半期でPUMA BIOTECHNOLOGY, INC.の売上複合成長率が高い（31.3% vs 22.7%）
プーマ・バイオテクノロジーは上場済みの生物医薬品企業で、本社はアメリカ合衆国カリフォルニア州ロサンゼルスに位置し、革新的な医薬品の研究開発を中心に事業を展開しています。
Viemed Healthcare, Inc.は呼吸ケアソリューションを専門とする医療テクノロジー企業で、携帯型人工呼吸器、呼吸療法機器および関連支援サービスを開発・製造・販売し、北米、欧州、アジア太平洋の急性期ケア、回復期ケア、在宅ケア分野で事業を展開しています。
PBYI vs VMD — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $75.5M | $76.2M |
| 純利益 | — | $5.6M |
| 粗利率 | 69.3% | 57.9% |
| 営業利益率 | 22.7% | 11.0% |
| 純利益率 | — | 7.4% |
| 売上前年比 | 27.7% | 25.5% |
| 純利益前年比 | — | 30.7% |
| EPS（希薄化後） | $0.26 | $0.14 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $75.5M | $76.2M | ||
| Q3 25 | $54.5M | $71.9M | ||
| Q2 25 | $52.4M | $63.1M | ||
| Q1 25 | $46.0M | $59.1M | ||
| Q4 24 | $59.1M | $60.7M | ||
| Q3 24 | $80.5M | $58.0M | ||
| Q2 24 | $47.1M | $55.0M | ||
| Q1 24 | $43.8M | $50.6M |
| Q4 25 | — | $5.6M | ||
| Q3 25 | $8.8M | $3.5M | ||
| Q2 25 | $5.9M | $3.2M | ||
| Q1 25 | $3.0M | $2.6M | ||
| Q4 24 | — | $4.3M | ||
| Q3 24 | $20.3M | $3.9M | ||
| Q2 24 | $-4.5M | $1.5M | ||
| Q1 24 | $-4.8M | $1.6M |
| Q4 25 | 69.3% | 57.9% | ||
| Q3 25 | 77.7% | 57.5% | ||
| Q2 25 | 76.5% | 58.3% | ||
| Q1 25 | 77.1% | 56.3% | ||
| Q4 24 | 76.4% | 59.5% | ||
| Q3 24 | 63.9% | 59.3% | ||
| Q2 24 | 77.4% | 59.8% | ||
| Q1 24 | 75.5% | 58.9% |
| Q4 25 | 22.7% | 11.0% | ||
| Q3 25 | 17.6% | 7.8% | ||
| Q2 25 | 12.7% | 8.1% | ||
| Q1 25 | 8.7% | 6.5% | ||
| Q4 24 | 22.6% | 10.6% | ||
| Q3 24 | 27.4% | 9.7% | ||
| Q2 24 | -4.6% | 6.6% | ||
| Q1 24 | -5.3% | 4.4% |
| Q4 25 | — | 7.4% | ||
| Q3 25 | 16.2% | 4.9% | ||
| Q2 25 | 11.2% | 5.0% | ||
| Q1 25 | 6.5% | 4.4% | ||
| Q4 24 | — | 7.1% | ||
| Q3 24 | 25.2% | 6.7% | ||
| Q2 24 | -9.6% | 2.7% | ||
| Q1 24 | -11.0% | 3.2% |
| Q4 25 | $0.26 | $0.14 | ||
| Q3 25 | $0.17 | $0.09 | ||
| Q2 25 | $0.12 | $0.08 | ||
| Q1 25 | $0.06 | $0.06 | ||
| Q4 24 | $0.40 | $0.10 | ||
| Q3 24 | $0.41 | $0.10 | ||
| Q2 24 | $-0.09 | $0.04 | ||
| Q1 24 | $-0.10 | $0.04 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $97.5M | $13.5M |
| 総負債低いほど良い | $22.7M | — |
| 株主資本純資産 | $130.3M | $141.5M |
| 総資産 | $216.3M | $199.2M |
| 負債/資本比率低いほどレバレッジが低い | 0.17× | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $97.5M | $13.5M | ||
| Q3 25 | $94.4M | $11.1M | ||
| Q2 25 | $96.0M | $20.0M | ||
| Q1 25 | $93.2M | $10.2M | ||
| Q4 24 | $101.0M | $17.5M | ||
| Q3 24 | $96.7M | $11.3M | ||
| Q2 24 | $96.8M | $8.8M | ||
| Q1 24 | $107.2M | $7.3M |
| Q4 25 | $22.7M | — | ||
| Q3 25 | $34.0M | — | ||
| Q2 25 | $45.3M | — | ||
| Q1 25 | $56.7M | — | ||
| Q4 24 | $68.0M | — | ||
| Q3 24 | $79.3M | — | ||
| Q2 24 | $90.7M | — | ||
| Q1 24 | $102.0M | — |
| Q4 25 | $130.3M | $141.5M | ||
| Q3 25 | $115.3M | $133.6M | ||
| Q2 25 | $104.7M | $139.7M | ||
| Q1 25 | $97.1M | $134.8M | ||
| Q4 24 | $92.1M | $131.4M | ||
| Q3 24 | $71.1M | $125.0M | ||
| Q2 24 | $48.5M | $119.4M | ||
| Q1 24 | $51.0M | $116.3M |
| Q4 25 | $216.3M | $199.2M | ||
| Q3 25 | $202.9M | $202.4M | ||
| Q2 25 | $194.9M | $184.6M | ||
| Q1 25 | $196.2M | $178.1M | ||
| Q4 24 | $213.3M | $177.1M | ||
| Q3 24 | $220.7M | $169.5M | ||
| Q2 24 | $205.0M | $163.9M | ||
| Q1 24 | $214.1M | $154.9M |
| Q4 25 | 0.17× | — | ||
| Q3 25 | 0.30× | — | ||
| Q2 25 | 0.43× | — | ||
| Q1 25 | 0.58× | — | ||
| Q4 24 | 0.74× | — | ||
| Q3 24 | 1.12× | — | ||
| Q2 24 | 1.87× | — | ||
| Q1 24 | 2.00× | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $14.4M | $18.4M |
| フリーキャッシュフロー営業CF - 設備投資 | $14.4M | $9.7M |
| FCFマージンFCF / 売上 | 19.1% | 12.7% |
| 設備投資強度設備投資 / 売上 | 0.0% | 11.5% |
| キャッシュ転換率営業CF / 純利益 | — | 3.27× |
| 直近12ヶ月FCF直近4四半期 | $41.7M | $11.9M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $14.4M | $18.4M | ||
| Q3 25 | $9.7M | $18.4M | ||
| Q2 25 | $14.1M | $12.3M | ||
| Q1 25 | $3.6M | $2.9M | ||
| Q4 24 | $15.6M | $15.0M | ||
| Q3 24 | $11.0M | $12.7M | ||
| Q2 24 | $1.0M | $10.2M | ||
| Q1 24 | $11.2M | $1.2M |
| Q4 25 | $14.4M | $9.7M | ||
| Q3 25 | $9.7M | $10.7M | ||
| Q2 25 | $14.1M | $4.1M | ||
| Q1 25 | $3.6M | $-12.6M | ||
| Q4 24 | $15.6M | $3.2M | ||
| Q3 24 | $11.0M | $1.7M | ||
| Q2 24 | $1.0M | $1.2M | ||
| Q1 24 | — | $-4.8M |
| Q4 25 | 19.1% | 12.7% | ||
| Q3 25 | 17.7% | 14.9% | ||
| Q2 25 | 26.8% | 6.5% | ||
| Q1 25 | 7.7% | -21.4% | ||
| Q4 24 | 26.4% | 5.2% | ||
| Q3 24 | 13.7% | 3.0% | ||
| Q2 24 | 2.1% | 2.3% | ||
| Q1 24 | — | -9.5% |
| Q4 25 | 0.0% | 11.5% | ||
| Q3 25 | 0.0% | 10.6% | ||
| Q2 25 | 0.0% | 12.9% | ||
| Q1 25 | 0.1% | 26.2% | ||
| Q4 24 | 0.0% | 19.5% | ||
| Q3 24 | 0.0% | 19.0% | ||
| Q2 24 | 0.0% | 16.3% | ||
| Q1 24 | 0.0% | 11.9% |
| Q4 25 | — | 3.27× | ||
| Q3 25 | 1.10× | 5.23× | ||
| Q2 25 | 2.41× | 3.88× | ||
| Q1 25 | 1.21× | 1.09× | ||
| Q4 24 | — | 3.47× | ||
| Q3 24 | 0.54× | 3.29× | ||
| Q2 24 | — | 6.94× | ||
| Q1 24 | — | 0.73× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
